New Tools for Quantifying HIV-1 Reservoirs: Plasma RNA Single Copy Assays and Beyond

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current HIV/AIDS Reports

• Publication date

  2012-01-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11904-011-0104-6PMID 22215419PMCID PMC3693463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

  2011cited by this paper
• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

  2011cited by this paper
• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

  2011cited by this paper
• Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

  2011cited by this paper
• Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

  2011cited by this paper
• Majority of CD4+ T cells from peripheral blood of HIV-1–infected individuals contain only one HIV DNA molecule

  2011cited by this paper
• Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

  2011cited by this paper
• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• Detection of HIV-1 at between 20 and 49 Copies per Milliliter by the Cobas TaqMan HIV-1 v2.0 Assay Is Associated with Higher Pretherapy Viral Load and Less Time on Antiretroviral Therapy

  2010cited by this paper
• Purging the HIV-1 reservoir through the disruption of the PD-1 pathway

  2010cited by this paper
• A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

  2010cited by this paper
• HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs

  2010cited by this paper
• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

  2010cited by this paper
• Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

  2010cited by this paper
• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

  2010cited by this paper
• HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection

  2010cited by this paper
• The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

  2010cited by this paper
• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

  2009cited by this paper
• Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

  2009cited by this paper
• Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

  2009cited by this paper
• Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

  2009influential reference
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

  2008cited by this paper
• Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

  2008cited by this paper
• The development and impact of 454 sequencing

  2008cited by this paper
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

  2008cited by this paper
• ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

  2007cited by this paper
• Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy

  2007cited by this paper
• The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone

  2006cited by this paper
• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

  2006cited by this paper
• Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

  2006cited by this paper
• Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis

  2005cited by this paper
• Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.

  2005cited by this paper
• Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.

  2005cited by this paper
• Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years

  2003cited by this paper
• New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma

  2003cited by this paper
• Prevalence and predictive value of intermittent viremia with combination hiv therapy.

  2001cited by this paper
• Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia

  2000cited by this paper
• Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection

  2000cited by this paper
• Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

  1999cited by this paper
• Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV.

  1998cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• Decay characteristics of HIV-1-infected compartments during combination therapy

  1997cited by this paper
• Detection of low HIV-1 RNA levels in plasma.

  1997cited by this paper
• Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

  1997cited by this paper
• HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

  1996cited by this paper
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

  1995cited by this paper
• Viral dynamics in human immunodeficiency virus type 1 infection

  1995cited by this paper
• In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus

  1991cited by this paper
• Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells.

  1991cited by this paper
• Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow

  1988cited by this paper
• The role of mononuclear phagocytes in HTLV-III/LAV infection.

  1986cited by this paper

• Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys

  2024influential citation
• High Genetic Diversity of HIV-1 and Active Transmission Clusters among Male-to-Male Sexual Contacts (MMSCs) in Zhuhai, China

  2023cites this paper
• Prevalence and risk of residual viremia after ART in low- and middle-income countries

  2021cites this paper
• Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs

  2020cites this paper
• Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection

  2020cites this paper
• HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus

  2019cites this paper
• Identification, Localization, and Quantification of HIV Reservoirs Using Microscopy

  2018cites this paper
• Molecular Testing for Human Imunodeficiency Virus

  2017cites this paper
• What Integration Sites Tell Us about HIV Persistence.

  2016cites this paper
• Animal Models for HIV Cure Research

  2016cites this paper
• HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy

  2016cites this paper
• Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers

  2016cites this paper
• Current views on HIV-1 latency, persistence, and cure

  2016cites this paper
• Nucleic Acids — The Use of Nucleic Acid Testing in Molecular Diagnostics

  2016cites this paper
• Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia

  2016cites this paper
• Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies

  2015cites this paper
• Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research

  2015cites this paper
• Cell-associated HIV RNA: a dynamic biomarker of viral persistence

  2013cites this paper
• Characterization of HIV-1 in the central nervous system during suppressive therapy

  2013cites this paper
• Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C

  2013cites this paper
• Neurocognitive Decline in HIV Infection

  2013cites this paper
• Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration

  2013cites this paper
• Nonhuman Primate Models for HIV Cure Research

  2012cites this paper
• Modeling Uncertainty in Single-Copy Assays for HIV

  2012cites this paper
• Towards an HIV cure: a global scientific strategy

  2012cites this paper